United Therapeutics Corporation $UTHR Shares Sold by Yousif Capital Management LLC

Yousif Capital Management LLC reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 6.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,004 shares of the biotechnology company’s stock after selling 995 shares during the period. Yousif Capital Management LLC’s holdings in United Therapeutics were worth $6,290,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the stock. Norges Bank purchased a new position in shares of United Therapeutics in the 2nd quarter valued at $136,453,000. Invesco Ltd. boosted its stake in United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after acquiring an additional 419,588 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of United Therapeutics by 40.1% during the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after purchasing an additional 364,713 shares during the last quarter. Amundi increased its position in shares of United Therapeutics by 198.8% during the first quarter. Amundi now owns 350,193 shares of the biotechnology company’s stock worth $107,635,000 after purchasing an additional 232,988 shares in the last quarter. Finally, Assetmark Inc. lifted its holdings in shares of United Therapeutics by 38.1% in the 2nd quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock valued at $205,695,000 after purchasing an additional 197,384 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on UTHR. Jefferies Financial Group restated a “buy” rating and set a $575.00 price target on shares of United Therapeutics in a research note on Wednesday, November 19th. Royal Bank Of Canada boosted their price objective on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research report on Wednesday, October 29th. UBS Group lifted their target price on shares of United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Finally, Oppenheimer upped their price target on shares of United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a research report on Friday, September 5th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $505.00.

Insider Activity

In related news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $450.24, for a total value of $10,130,400.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 599,664 shares of company stock worth $274,775,331 in the last quarter. Insiders own 10.30% of the company’s stock.

United Therapeutics Price Performance

United Therapeutics stock opened at $513.99 on Thursday. The business has a 50 day simple moving average of $468.27 and a 200-day simple moving average of $384.93. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $519.99. The stock has a market capitalization of $22.13 billion, a PE ratio of 19.48, a price-to-earnings-growth ratio of 5.07 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. During the same period in the previous year, the company posted $6.39 EPS. United Therapeutics’s revenue was up 6.8% compared to the same quarter last year. As a group, equities research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.